2022 Fiscal Year Final Research Report
Development of a completely new antibody-cell complex advanced technology that overcomes the limitations of allogeneic CAR-T therapy.
| Project/Area Number |
21K19529
|
|---|
| Research Category |
Grant-in-Aid for Challenging Research (Exploratory)
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Medium-sized Section 55:Surgery of the organs maintaining homeostasis and related fields
|
|---|
| Research Institution | Kyushu University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2021-07-09 – 2023-03-31
|
| Keywords | NK細胞 / 抗体医薬 / 固形腫瘍 / CAR-T / がん免疫 / 他家細胞 |
|---|
| Outline of Final Research Achievements |
We have selected NKp46, 2B4, and NKp30 as target molecules on GAIA-102 and conducted selection of monobodies that specifically bind to these target molecules. All clones were confirmed to bind to GAIA-102. In addition, we designed scFv based on known antibody sequences and fusion proteins with monobody for functional evaluation of GAIA-102 binding monobodies. These research results provide valuable data for the development of advanced "antibody-cell complex" technology as intended and will now move on to the practical development steps for standardization and manufacturing towards clinical development.
|
| Free Research Field |
外科学、病理学、腫瘍免疫学
|
| Academic Significance and Societal Importance of the Research Achievements |
難治性悪性腫瘍に対し、期待されながらも製剤化の困難に直面する他家CAR-T(キメラ遺伝子導入T細胞治療)の限界を突破するために、独自特許技術であるNK細胞製剤GAIA-102 (AMEDの支援にて開発中)の機能を更に高度化するための遺伝子導入技術を用いず既存抗体医薬品の全てに適応可能な「抗体・細胞複合体」高度化技術を開発することで、未だ治療成果が十分では無い広範な悪性腫瘍に有効な治療法を提供する。
|
